Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

OTCPK:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Nuance

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon Aug 20, 2021 11:12pm

283 Views

Post# 33744369

RE:Nuance

That question was asked in the AGM if nuance would proceed with ph3. Dan said they can’t. ATE is still running show, nuance is flipping the bill.

Rarbar99 wrote:
Nuance Pharma is also in the process of developing/testing this drug in China. Have the board said anything about them in yesterday's meeting? What if the Chinese don't care about these elevated levels and are still proceeding with the testing without delays?

There's still $80 million dollars on the line from their part, this should be a big focal point of the topic IMO.

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success